Pharmacokinetic modelling and development of bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation

Clinical Pharmacokinetics

Volumn 48, Issue 10, 2009, Pages 667-675

  Saint Marcoux, Franck ^a   Royer, Bernard ^b   Debord, Jean ^a   Larosa, Fabrice ^c   Legrand, Faezeh ^c   Deconinck, Eric ^b   Kantelip, Jean Pierre ^a   Marquet, Pierre ^a,c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG MONITORING; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BAYES THEOREM; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MYCOPHENOLIC ACID; PHARMACOKINETICS; PILOT PROJECTS; PRODRUGS; YOUNG ADULT;

EID: 70349150462     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317140-000000000-00000     Document Type: Article

References (37)

1. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006 Oct 27; 82 (8): 1004-1012
2. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 Apr; 28 (2): 145-154
3. Basara N, Blau WI, Kiehl MG, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc 1998 Dec; 30 (8): 4087-4089 (Pubitemid 29013165)
4. Basara N, Blau WI, Kiehl MG, et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 2000 Apr; 14 (2): 121-126
5. Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002 Sep; 30 (5): 287-295
6. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004 Oct; 34 (7): 621-625
7. Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999 Feb 27; 67 (4): 499-504
8. Giaccone L, McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005 Dec 15; 106 (13): 4381-4388
9. Kiehl MG, Schafer-Eckart K, Kroger M, et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. Transplant Proc 2002 Nov; 34 (7): 2922-2924
10. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003 Sep 15; 102 (6): 2021-2030
11. Mohty M, de Lavallade H, Faucher C, et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004 Sep; 34 (6): 527-530 (Pubitemid 39264044)
12. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versushost disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol BloodMarrow Transplant 2005 Jul; 11 (7): 495-505
13. Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolate mofetil versus cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation fromHLA-identical siblings. Bone Marrow Transplant 2005 Jun; 35 (11): 1089-1093
14. van Hest RM, Doorduijn JK, de Winter BC, et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 2007 Jun; 29 (3): 353-360
15. Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001 Jun; 27 (12): 1255-1262
16. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008 Jun 27; 85 (12): 1675-1685
17. Premaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet 2005; 44 (8): 837-847
18. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther DrugMonit 2005 Jun; 27 (3): 354-361
19. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007 Nov; 7 (11): 2496-2503
20. Saint-Marcoux F, Debord J, Hoizey G, et al. Statistics of MMF dose adjustment on ISBA, a free website for dose adjustment of immunosuppressive drugs [abstract]. Ther Drug Monit 2007; 29 (4): 241
21. Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol BloodMarrow Transplant 2006 Apr; 12 (4): 454-465
22. Haentzschel I, Freiberg-Richter J, Platzbecker U, et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant 2008 Jul; 42 (2): 113-120
23. Larosa F, Marmier C, Robinet E, et al. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. Bone Marrow Transplant 2005 May; 35 (9): 859-868
24. Na-Bangchang K, Supasyndh O, Supaporn T, et al. Simple and sensitive highperformance liquid chromatographic. J Chromatogr B Biomed Sci Appl 2000 Jan 28; 738 (1): 169-173
25. Zahr N, Amoura Z, Debord J, et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet 2008; 47 (4): 277-284
26. Debord J,Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40 (5): 375-382
27. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet 2005; 44 (12): 1317-1328
28. Proost JH, Eleveld DJ. Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res 2006 Dec; 23 (12): 2748-2759
29. Steimer JL,Mallet A, Golmard JL, et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 1984; 15 (1-2): 265-292
30. D'Argenio DZ. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math Biosci 1990 Apr; 99 (1): 105-118
31. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9 (4): 503-552
32. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003 Aug; 56 (2): 205-213
33. Irtan S, Saint-Marcoux F,Rousseau A, et al. Population pharmacokinetics and Bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 2007 Feb; 29 (1): 96-102
34. Jacobson P, Rogosheske J, Barker JN, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005 Nov; 78 (5): 486-500
35. Huang J, Jacobson P, Brundage R. Prediction of unbound mycophenolic acid concentrations in patients after hematopoietic cell transplantation. Ther Drug Monit 2007 Aug; 29 (4): 385-390 (Pubitemid 47220453)
36. Ng J, Rogosheske J, Barker J, et al. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 2006 Jun; 28 (3): 394-401
37. US FDA Center for Drug Evaluation and Research [CDER]. Guidance for industry: population pharmacokinetics. Rockville (MD): CDER, 1999 Feb [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf [Accessed 2009 Aug 5]